What is Shiga toxin-producing E. coli hemolytic uremic syndrome (STEC-HUS)?

Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... Oct 3, 2024 ... - Soliris is a complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; atypical ... Apr 1, 2024 ... SOLIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. SOLIRIS increases ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... SOLIRIS (eculizumab) is an FDA-approved prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ...